PARP抑制剂在小细胞肺癌靶向治疗中的进展

Progress of PARP inhibitors in targeted therapy of small cell lung cancer

小细胞肺癌(SCLC)是一种发展迅速的恶性肿瘤,具有高度异质性并易产生耐药,预后通常不佳。多聚ADP核糖聚合酶(PARP)抑制剂可靶向作用于DNA损伤反应通路,阻止DNA修复,从而发挥抗肿瘤作用。目前在SCLC治疗方案中既有PARP抑制剂单药治疗,也有与DNA损伤剂或免疫检查点抑制剂联合治疗。尽管目前研究结果有限,但可以看到PARP抑制剂可能是SCLC靶向治疗的突破口。

Small cell lung cancer(SCLC)is a rapidly developing malignant tumor,which is highly heterogeneous and prone to drug resistance,and the prognosis is usually poor.Poly ADP-ribose polymerase(PARP)inhibitors target the DNA damage response pathway,preventing DNA repair,thereby exerting anti-tumor effects.Currently,PARP inhibitors are used as monotherapy or in combination with DNA-damaging agents or immune checkpoint inhibitors in the treatment of SCLC.Although the current research results are limited,it can be seen that PARP inhibitors may be a breakthrough in the targeted therapy of SCLC.